Skip to main content

Primary Hyperoxaluria News

Related terms: Oxalosis, PH, PH1

FDA Approves Rivfloza (nedosiran) for the Treatment of Primary Hyperoxaluria Type 1 (PH1)

PLAINSBORO, N.J., Oct. 2, 2023 /PRNewswire/ – Novo Nordisk announced today that the U.S. Food and Drug Administration (FDA) has approved Rivfloza (nedosiran) injection 80 mg, 128 mg, or 160 mg, a ...

Alnylam Announces FDA Approval of Supplemental New Drug Application for Oxlumo (lumasiran) in Advanced Primary Hyperoxaluria Type 1

Oxlumo Now Indicated for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary and Plasma Oxalate Levels in Pediatric and Adult Patients Approval is Based on Positive Efficacy and...

Ask a question

To post your own question to this support group, sign in or create an account.